CN Patent

CN102532116B — 抗肿瘤靶向治疗药物tivozanib的合成方法

Assigned to Wuhan Madesin Pharmaceutical Technology Co ltd · Expires 2015-01-21 · 11y expired

What this patent protects

本发明涉及一种抗肿瘤靶向治疗药物tivozanib的合成路线，以邻苯二甲醚为起始原料，通过付克酰基化、硝化、还原、加成消除、氯化和缩合取代反应等7步反应合成tivozanib。本发明的合成原料廉价易得，反应条件温和，工艺稳定，成本低和收率高等优点，因此本发明是一种适合工业化生产tivozanib的方法。

USPTO Abstract

本发明涉及一种抗肿瘤靶向治疗药物tivozanib的合成路线，以邻苯二甲醚为起始原料，通过付克酰基化、硝化、还原、加成消除、氯化和缩合取代反应等7步反应合成tivozanib。本发明的合成原料廉价易得，反应条件温和，工艺稳定，成本低和收率高等优点，因此本发明是一种适合工业化生产tivozanib的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN102532116B
Jurisdiction
CN
Classification
—
Expires
2015-01-21
Drug substance claim
No
Drug product claim
No
Assignee
Wuhan Madesin Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.